ArticleKidney international reports2021

Treatment of Concurrent Minimal Change Disease and Epstein Barr Virus-Driven Post-transplant Lymphoproliferative Disorder With Rituximab Following Hematopoietic Stem Cell Transplantation.

Louise Ainley et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.